 Crinetics Pharmaceuticals, Inc. CRNX, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics. 